Billing Beat

COVID-19: In Vitro Diagnostic Testing Policy 0557


U0003 Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R (Code deleted 5/11/2023)

U0004 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R (Code deleted 5/11/2023)

U0005 Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (List separately in addition to either HCPCS code U0003 or U0004) as described by CMS-2020-01-R2 (Code deleted 5/11/2023)

Source: https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_Future/mm_0557_coveragepositioncriteria_covid-19_in_vitro_diagnostic_testing.pdf

Cigna

Sign up for Billing Beat